by Peter Ciszewski | Sep 26, 2017
A randomized clinical trial of 766 patients shows that a simple intervention — a web-based tool that enables patients to report their symptoms in real time, triggering alerts to clinicians — can have major benefits, including longer survival. Patients...
by Peter Ciszewski | Sep 26, 2017
In an early clinical trial, 33 out of 35 (94%) patients had clinical remission of multiple myeloma upon receiving a new type of immunotherapy, chimeric antigen receptor (CAR) T cells targeting B-cell maturation protein (BCMA). Most patients had only mild side effects....
by Peter Ciszewski | Sep 26, 2017
Genomic testing of tumor samples can enable personalized treatment selection, where targeted treatments are matched to genetic changes in the tumor. Although a growing number of patients with advanced cancers receive some genomic testing, comprehensive genomic testing...
by Peter Ciszewski | Sep 26, 2017
Sickle Cell Disease and Beta-thalassemia are two severe diseases that are caused by defects in the beta-globin protein in hemoglobin, present in red blood cells. Patients born with Sickle Cell Disease and Beta-thalassemia do not have symptoms when they are first born...
by Peter Ciszewski | Sep 26, 2017
X4 Pharmaceuticals, a clinical stage biotechnology company developing a novel CXCR4 inhibitor drug to improve immune cell trafficking to treat cancer and rare diseases, today announced Phase 1 results from the company’s ongoing Phase 1/2 study of X4P-001-IO. The data...
